期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 35, 期 3, 页码 211-218出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2009.09.020
关键词
Breakthrough infection; Echinocandin; Mycoses; Candida
资金
- Pfizer
- Schering-Plough
- Enzon
The echinocandins have emerged as important antifungal agents in the current era. Despite their potent antifungal activity, breakthrough invasive mycoses occur in echinocandin recipients, however their precise incidence and causative pathogens are not well delineated. This review shows that breakthrough mycoses occur in 2.4% of patients receiving echinocandins as prophylaxis and are predominantly due to non-albicans Candida spp. and less frequently to invasive aspergillosis. Candida isolates demonstrating reduced susceptibility occurred following prolonged exposure to the echinocandins, primarily in severely immunocompromised patients, and manifested as recurrent episodes of candidaemia or invasive candidiasis. Published by Elsevier B.V. on behalf of International Society of Chemotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据